Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 11;9(2):e12388.
doi: 10.1002/trc2.12388. eCollection 2023 Apr-Jun.

Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials

Christopher H Van Dyck  1 , Ryan S O'Dell  1 , Adam P Mecca  1
Affiliations

Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials

Christopher H Van Dyck et al. Alzheimers Dement (N Y). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

C.H.v.D. has received compensation for consulting services from Eisai, Roche, Ono, and Cerevel and has received grant support for the conduct of multicenter therapeutic trials from Eli Lilly, Biogen, Roche, Genentech, UCB, Cerevel, and Biohaven. A.P.M. has received grant support for the conduct of multicenter therapeutic trials from Eli Lilly, Janssen, Roche, and Eisai. No conflict of interest is reported for R.S.O.Author disclosures are available in the supporting information.

References

    1. Andrews JS, Desai U, Kirson NY, Zichlin ML, Ball DE, Matthews BR. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials. Alzheimers Dement (N Y). 2019;5:354‐363. - PMC - PubMed
    1. Liu KY, Schneider LS, Howard R. The need to show minimum clinically important differences in Alzheimer's disease trials. Lancet Psychiatry. 2021;8(11):1013‐1016. doi:10.1016/S2215-0366(21)00197-8 - DOI - PubMed
    1. Van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab for treatment of early Alzheimer's disease. N Engl J Med. 2023;388(1):9‐21. doi:10.1056/NEJMoa2212948 - DOI - PubMed
    1. Walsh S, Merrick R, Richard E, Nurock S, Brayne C. Lecanemab for Alzheimer's disease. BMJ. 2022;379:o3010. doi:10.1136/bmj.o3010 - DOI - PubMed
    1. Information and Resources. NACC researcher home page , National Alzheimers Coordinating Center. University of Washington. https://www.alz.washington.edu/WEB/researcher_home.html